Media Center

All news News

  • 21 February 2018

    Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia

    Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia

    Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of urogenital chlamydia in women.

  • 20 February 2018

    Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule

    Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule

    Evofem Biosciences, Inc., (NASDAQ: EVFM), a biotechnology company developing innovative products to fill women's unmet healthcare needs, announced early completion of enrollment in its Phase 3 clinical trial evaluating Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of pregnancy. Trial data is expected in the first quarter of 2019.

  • 08 February 2018

    Epic Sciences To Present Single Cell PSMA Analysis To Provide Insight Into Tumor Heterogeneity And Links To Response With Anti-PSMA Therapy

    Epic Sciences To Present Single Cell PSMA Analysis To Provide Insight Into Tumor Heterogeneity And Links To Response With Anti-PSMA Therapy

    Epic Sciences, Inc. (Epic) announces that it will present data, in conjunction with Endocyte, Inc., comparing its proprietary single cell CTC analysis to PSMA targeted imaging in mCRPC patients to provide insight into disease heterogeneity and identify potential therapeutic resistance mechanisms.

  • 07 February 2018

    NovaMedica R&D Center will become a training facility for implementation of modern pharmaceutical technologies

    NovaMedica R&D Center will become a training facility for implementation of modern pharmaceutical technologies

    Russian pharmaceutical company NovaMedica (investment project of Rusnano) announces start of its cooperation in the area of transfer of knowledge and technologies between the R&D Center of NovaMedica Innotech and the German company Evonik – one of the leading companies in the international market of excipients manufacturing for the pharmaceutical industry. This partnership will result into creation of a training facility for transfer of competences in the area of pharmaceutical technologies at the premises of NovaMedica Innotech in Russia.

  • 01 February 2018

    Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines

    Celtaxsys announces the issue of four new patents expanding its pipeline of selective leukotriene B4 modulation anti-inflammatory medicines

    Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, announced today the issuance of four new patents, extending its leadership position in development of a robust pipeline of inhibitors of Leukotriene A4 Hydrolase (LTA4H), the key rate limiting enzyme in production of the inflammatory mediator Leukotriene B4 (LTB4).  LTB4 is a potent mediator of neutrophil activity and when over-expressed, can lead to hyper-activation of neutrophils, resulting in sustained inflammation, tissue damage and reduced organ function, including in the lungs of CF patients. 

  • 01 February 2018

    Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

    Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced a new clinical collaboration with AstraZeneca  to evaluate the safety and efficacy of AstraZeneca's durvalumab, a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with SNDX-6352, Syndax's monoclonal antibody inhibitor of Colony-Stimulating Factor 1 Receptor (CSF1R), across a variety of solid tumors.

  • 25 January 2018

    Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

    Evofem Biosciences Announces First Patient Enrolled in Phase 2b/3 STI Trial of Amphora® and Expects Phase 3 Contraceptive Clinical Trial Data First Quarter 2019

    Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage specialty biopharmaceutical company focused on the development and commercialization of women's healthcare products, today announced enrollment of the first patient in a Phase 2b/3 clinical trial evaluating Amphora and its ability to prevent urogenital chlamydia and gonorrhea in women.  Amphora is an investigational compound being studied for the prevention of certain reproductive tract infections and as an on-demand, non-hormonal vaginal contraceptive.

  • 18 January 2018

    Evofem Announces Closing Of Merger With Neothetics

    Evofem Announces Closing Of Merger With Neothetics

    Evofem Biosciences, Inc. (NASDAQ: EVFM), today announced the closing of the previously announced merger with Neothetics, Inc. (NASDAQ: NEOT).  The merged company will operate as Evofem Biosciences, Inc. and will focus on the continued development and commercialization of women's healthcare products. 

  • 10 January 2018

    Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

    Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer

    Syndax Pharmaceuticals, Inc.  ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced a new clinical collaboration with  Genentech , a member of the Roche Group. As part of the collaboration, the two companies will evaluate the combination of Syndax's entinostat, an oral, small molecule, class I HDAC inhibitor, and  Genentech's  programmed cell death ligand 1 (PD-L1) blocking antibody, atezolizumab (TECENTRIQ®), in patients with second-line hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+, HER2-) metastatic breast cancer.

  • 05 January 2018

    Life Sciences Pioneer Stanley Lapidus Joins Atlas Genetics Board of Director

    Life Sciences Pioneer Stanley Lapidus Joins Atlas Genetics Board of Director

    Atlas Genetics, a rapid, near-patient and point-of-care (POC) testing company, today announced that it has appointed Stanley Lapidus to the role of independent board member on its Board of Directors. Lapidus has more than 30 years’ experience in the medical diagnostics industry as a founder, CEO and board member at companies that have dramatically impacted the diagnostics landscape, including his founding of EXACT Sciences Corp. (NASDAQ:EXAS) and, prior to that, Cytyc Corp., which was sold to Hologic Corporation in 2007.

All publications Media about us